Buformin inhibits the stemness of erbB-2-overexpressing breast cancer cells and premalignant mammary tissues of MMTV-erbB-2 transgenic mice

BACKGROUND: Metformin, an FDA-approved drug for the treatment of Type II diabetes, has emerged as a promising anti-cancer agent. Other biguanide analogs, including buformin and phenformin, are suggested to have similar properties. Although buformin was shown to reduce mammary tumor burden in carcino...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Exp Clin Cancer Res
Main Authors: Parris, Amanda B., Zhao, Qingxia, Howard, Erin W., Zhao, Ming, Ma, Zhikun, Yang, Xiaohe
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2017
Teme:
Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5307817/
https://ncbi.nlm.nih.gov/pubmed/28193239
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-017-0498-0
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki